Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Precigen, Inc. (PGEN : NSDQ)
 
 • Company Description   
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.

Number of Employees: 194

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.67 Daily Weekly Monthly
20 Day Moving Average: 1,448,113 shares
Shares Outstanding: 206.74 (millions)
Market Capitalization: $758.73 (millions)
Beta: 2.30
52 Week High: $11.10
52 Week Low: $3.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.23% -28.05%
12 Week -41.09% -41.68%
Year To Date -64.02% -67.90%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
20374 Seneca Meadows Parkway
-
Germantown,MD 20876
USA
ph: 301-556-9900
fax: -
investors@precigen.com http://www.precigen.com
 
 • General Corporate Information   
Officers
Helen Sabzevari - Chief Executive Officer
Randal J. Kirk - Chairman
Rick L. Sterling - Chief Financial Officer
Cesar L. Alvarez - Director
Steven Frank - Director

Peer Information
Precigen, Inc. (CORR.)
Precigen, Inc. (RSPI)
Precigen, Inc. (CGXP)
Precigen, Inc. (BGEN)
Precigen, Inc. (GTBP)
Precigen, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74017N105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 03/07/22
Share - Related Items
Shares Outstanding: 206.74
Most Recent Split Date: (:1)
Beta: 2.30
Market Capitalization: $758.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/07/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.78
Price/Cash Flow: -
Price / Sales: 7.67
EPS Growth
vs. Year Ago Period: -25.00%
vs. Previous Quarter: -50.00%
Sales Growth
vs. Year Ago Period: -8.57%
vs. Previous Quarter: -35.79%
ROE
09/30/21 - -68.90
06/30/21 - -70.74
03/31/21 - -83.29
ROA
09/30/21 - -24.44
06/30/21 - -22.27
03/31/21 - -20.54
Current Ratio
09/30/21 - 5.28
06/30/21 - 5.43
03/31/21 - 5.71
Quick Ratio
09/30/21 - 4.94
06/30/21 - 5.03
03/31/21 - 5.29
Operating Margin
09/30/21 - -92.65
06/30/21 - -80.49
03/31/21 - -74.49
Net Margin
09/30/21 - -109.91
06/30/21 - -107.46
03/31/21 - -134.74
Pre-Tax Margin
09/30/21 - -112.68
06/30/21 - -108.15
03/31/21 - -107.25
Book Value
09/30/21 - 0.63
06/30/21 - 0.77
03/31/21 - 0.85
Inventory Turnover
09/30/21 - 5.28
06/30/21 - 5.03
03/31/21 - 4.87
Debt-to-Equity
09/30/21 - 1.37
06/30/21 - 1.11
03/31/21 - 1.00
Debt-to-Capital
09/30/21 - 57.81
06/30/21 - 52.64
03/31/21 - 49.91
 

Powered by Zacks Investment Research ©